Skip to main content
Hematology and Oncology
ALL Specialities
ALL Specialities
/
Hematology and Oncology
Blood & Cancer Podcast
CME
Diseases & Conditions
Nonmalignant Hematologic Disorders
Anemia
Bleeding Disorders
Thrombosis
Breast Cancer
CNS/Brain Cancer
Gastrointestinal Cancer
Genitourinary Cancer
Renal Cell Carcinoma
Gynecologic Cancer
Head & Neck/Thyroid Cancers
Leukemia, Myelodysplasia, Transplantation
ALL
AML
Cellular Therapy
CLL
CML
Myelodysplastic Syndrome
Transplantation
Lung Cancer
Lymphoma & Plasma Cell Disorders
B Cell Lymphoma
Follicular Lymphoma
Hodgkin Lymphoma
Mantle Cell Lymphoma
Multiple Myeloma
Non-Hodgkin Lymphoma
T Cell Lymphomas
Melanoma
Nonmelanoma Skin Cancer
Sarcoma and GIST
COVID-19 Updates
Conference Coverage
News
JAK inhibitor more effective than standard therapy for polycythemia vera
Publish date:
January 28, 2015
FROM THE NEW ENGLAND JOURNAL OF MEDICINE
References
emechcatie@frontlinemedcom.com
Pages
« first
1
2
Recommended Reading
Update on therapies for lymphoproliferative disorders
MDedge Hematology and Oncology
Why EBV-positive lymphomas resist IFN therapy
MDedge Hematology and Oncology
EMA wants to suspend drugs due to data manipulation
MDedge Hematology and Oncology
Gains in CLL are ‘Advance of the Year’
MDedge Hematology and Oncology
Label changes report new side effects for hematology drugs
MDedge Hematology and Oncology
NHS cuts 5 blood cancer drugs from CDF, adds 1
MDedge Hematology and Oncology
Protein may hold key to treating resistant lymphomas
MDedge Hematology and Oncology
Survey reveals cancer survivors’ unmet needs
MDedge Hematology and Oncology
Biopsies don’t promote cancer spread, group finds
MDedge Hematology and Oncology
Product gets fast track designation for CTCL
MDedge Hematology and Oncology
Lymphoma & Plasma Cell Disorders
Bleeding Disorders
All Specialties
